ArticleInfluenza and other respiratory viruses2021
ROSES-S: Statement from the World Health Organization on the reporting of seroepidemiologic studies for SARS-CoV-2.
Article in Influenza and other respiratory viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Adherence of SARS-CoV-2 Seroepidemiologic Studies to the ROSES-S Reporting Guideline During the COVID-19 Pandemic.Influenza and other respiratory viruses · 2024Pooled it
- The increasing complexity of arbovirus serology: An in-depth systematic review on cross-reactivity.PLoS neglected tropical diseases · 2023Pooled it
- Household transmission investigation: Design, reporting and critical appraisal.Influenza and other respiratory viruses · 2023Pooled it
- A framework for seroepidemiologic investigations in future pandemics: insights from an evaluation of WHO's Unity Studies initiative.Health research policy and systems · 2023Pooled it
- Transmission of SARS-CoV-2 in standardised first few X cases and household transmission investigations: A systematic review and meta-analysis.Influenza and other respiratory viruses · 2022Pooled it
- SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021.BMJ global health · 2022Pooled it
- Seroprevalence of IgG antibodies against SARS-CoV-2 in India, March 2020 to August 2021: a systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Pooled it
- Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis.PloS one · 2021Pooled it
- A Bayesian modelling framework to improve antibody titer estimation applied to RSV dilution series data.Nature communications · 2026Article
- Lack of harmonisation in immunological data: challenges in synthesising data during the COVID-19 pandemic.EBioMedicine · 2026Review
- Risk factors for recognized and unrecognized SARS-CoV-2 infection: a seroepidemiologic analysis of the Prospective Urban Rural Epidemiology (PURE) study.Microbiology spectrum · 2024Article
- Using Regional Sero-Epidemiology SARS-CoV-2 Anti-S Antibodies in the Dominican Republic to Inform Targeted Public Health Response.Tropical medicine and infectious disease · 2023Article
- SARS-CoV-2 seroprevalence and determinants for salivary seropositivity among pupils and school staff: a prospective cohort study.Epidemiology and infection · 2023Article
- Timeliness of reporting of SARS-CoV-2 seroprevalence results and their utility for infectious disease surveillance.Epidemics · 2022Article
- U.S. CDC support to internationalPLOS global public health · 2022Article
- Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.JAMA network open · 2022Article
- Seroprevalence of SARS-CoV-2 in a Large Cohort of Italian Police Officers.International journal of environmental research and public health · 2021Article
- ROSES-S: Statement from the World Health Organization on the reporting of seroepidemiologic studies for SARS-CoV-2.Influenza and other respiratory viruses · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Well-designed population-based seroepidemiologic studies can be used to refine estimates of infection severity and transmission, and are therefore an important component of epidemic surveillance. However, the interpretation of the results of seroepidemiologic studies for SARS-CoV-2 has been hampered to date principally by heterogeneity in the quality of the reporting of the results of the study and a lack of standardized methods and reporting. We provide here the ROSES-S: Reporting of Seroepidemiologic studies-SARS-CoV-2. This is an updated checklist of 22 items that should be included in the reporting of all SARS-CoV-2 seroepidemiologic studies, irrespective of study design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.